Abstract

ObjectivesChronic osteoarthritis of knee is very commonly encountered in clinical practice. Pain relief and restoration of physical function are the targets of therapy. This study aims to compare the efficacy and safety of tapentadol with etoricoxib in the management of osteoarthritis of knee. MethodsThis is a randomised, open labelled, controlled study in which patients received either tablet tapentadol (100mg twice daily) or etoricoxib (30mg twice daily) for 12 weeks. Follow-up was done after 2nd, 4th, 8th and 12th weeks of initiation of treatment and also after 2 weeks of treatment completion. Assessment of improvement in pain perception on Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) sub-score for stiffness and physical function were performed. Results108 patients receiving tapentadol and 110 patients receiving etoricoixb were analysed on Intention to Treat basis. Steady improvement was seen in VAS and WOMAC scores in both the groups, though there was no significant difference between the groups. Clinical Global Impression measured by physician showed significant difference between groups with greater number of patients experiencing at least satisfactory response at the end of the study in the tapentadol group (p=0.036). The total number of adverse events was less with tapentadol than etoricoxib. ConclusionsTapentadol is as effective as etoricoxib in the management of mild to moderate grades of chronic osteoarthritis of knee with lower incidences of adverse effects.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call